Clinical Trials Logo

Clinical Trial Summary

This study aims to understand how vitamin D (VD) affects human health. Typically, prisoners are low on vitamin D, as it is difficult to receive through diet, and is mostly obtained via exposure to the sun. The investigators predict that VD supplements could help improve overall mental well-being, as well as improve bone health. The investigators aim to recruit two groups of participants from a United Kingdom (UK) Prison, all of whom will participate via an informed consent process. The first group of prisoners will have chosen to take VD supplements, the second group will have chosen not to take VD supplements. At the start of the study, prisoners will have their bone density and blood VD levels tested. The investigators will also ask participants to complete a series of questionnaires to understand the state of mental well-being at the start of the study. Participants will be asked to complete a food diary to track dietary intake over the following week. Additionally, the investigators are interested in identifying what proportion of participants have a specific genetic makeup relating to their ability to metabolise VD, and participants will be asked to provide a saliva sample to test this. Every month following the start of the study, participants will be asked to complete the same questionnaires and food diary again. On the 3rd month, the investigators will again test the participants' bone density and blood levels of VD, to see whether supplementation has improved participant VD status. This study will run for a minimum of 3 months, up to a maximum of 6.


Clinical Trial Description

Aim of this research: This is a quantitative open-label controlled trial, aiming to assess the effect of VD supplementation, within offender populations (male adults 21+), on behaviours, physical and mental health outcomes. Primary Aims: 1. To assess the prevalence of VD supplementation within prisons. 2. To assess VD serum levels among male adult prisoner population. 3. To assess whether VD supplementation in prisons can lead to improved markers of physical health, for example, grip strength, bone density. 4. To assess whether VD supplementation in prisons can lead to an overall improvement of mental health wellbeing, including anxiety and depression severity, assessed using validated methods. 5. To assess whether VD can lead to improved behaviour amongst prisoners, assessed using a self-reported aggression questionnaire, and governor adjudication reports. Secondary Aims: 1. To determine whether aim 2 is associated with individual differences in VD metabolism. 2. To assess overall nutritional content and quality of prison dietary intake. This research has five hypotheses: 1. VD supplementation will improve Serum 25-hydroxyvitamin D (VD) levels. 2. VD supplementation will reduce levels of anxiety and depression within the offender population (measured by GAD-7 and PHQ-9). 3. VD will improve general mental well-being (measured by WEMWBS). 4. VD supplementation will improve physical health outcomes within the offender population (measured by VD blood serum level, bone density, and grip strength) 5. VD supplementation will reduce violence and aggressive behaviours (measured by Buss Perry AQ, and adjudication reports) Study Design: A minimum of 100 participants (50 per group) will be sought for recruitment (+10% for attrition). The sample size is based on The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) which ideally recommends a minimum of 50 participants per group (100 total) to detect a difference of +/- 5 points. This sample size is calculated using a power of 0.8, at a significance level of 0.05. Group 1 (experimental group) will be supplemented with VD (1x25ug VD3 cholecalciferol tablet per day), and group 2 will not be supplemented with VD (control group). Upon recruitment, participants will be identified as either taking VD, or not. Participants taking VD will be in Group 1, participants not taking VD will be in Group2 (control). Baseline Measures: From Participant: 1. Demographic information: (age, sex, ethnicity/race, gender, level of education, custodial status and length) 2. Health measures: (height, weight, body mass index (BMI), grip strength) 3. Dietary intake: food diary (7-day food diary will be provided to participants) 4. Self-Reported Questionnaires: Patient Health Questionnaire-9 (PHQ-9) (for depression), Generalised Anxiety Disorder Assessment (GAD-7) (for anxiety), Buss Perry Aggression Questionnaire (AQ) (for aggression), and WEMWBS (for general mental wellbeing) 5. A survey question regarding time spent outside on average, and the date participant first took supplement (if applicable) 6. Bone density 7. Blood analysis (for VD serum) (researcher will be qualified for blood-taking procedures) 8. Saliva analysis (for genetics) From Prison 1. Health history (including medications taking) 2. Behaviour records (governor/officer reports, adjudication reports) 3. Mental health history (i.e. any diagnoses/treatment for depression, anxiety, bipolar, schizophrenia, any reports of self-harm/suicide attempts) 4. Substance use (any misuse history) 5. Dietary issues (history of hunger strikes) 6. Date of resident entry to prison and length of stay After baseline, the following measures will be taken at the end of month 1 and month 2: From Participant: 1. Questionnaires: PHQ-9, GAD-7, AQ, and WEMWBS 2. Log/Question regarding time spent outside At the end of month 3, the following measures will be taken: From Participant: 1. Blood analysis: Serum 25-hydroxyvitamin D (25(OH)D) 2. Bone density 3. Grip strength 4. Weight, height, and BMI 5. 3- or 7-day food diary (will depend on what is discussed with identified prisons) And the regular monthly measures: 1. Questionnaires: PHQ-9, GAD-7, AQ, and WEMWBS 2. Log/Question regarding time spent outside ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05724316
Study type Interventional
Source Oxford Brookes University
Contact Jonathan Tammam
Phone +44 (0)1865 483245
Email jtammam@brookes.ac.uk
Status Recruiting
Phase N/A
Start date March 18, 2023
Completion date March 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3